manufacturer/tradename
Milliplex®
species reactivity
human
packaging
pkg of 1 ea
technique(s)
multiplexing: suitable
input
serum plasma (Cell culture, cell culture supernatants)
detection method
fluorometric (Luminex® xMAP® technology)
shipped in
wet ice
storage temp.
2-8°C
General description
Application
Analytes included: BTLA (B- and T-lymphocyte attenuator), CD27 (Cluster of differentiation 27), CD28 (Cluster of differentiation 28), CD40 (Cluster of differentiation 40), CD80/B7-1 (Cluster of differentiation 80/B7-1), CD86/B7-2 (Cluster of differentiation 86/B7-2), CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), GITRL (Ligand for receptor TNFRSF18/AITR/GITR), GITR (Glucocorticoid-induced TNFR-related protein), HVEM (Herpesvirus entry mediator), ICOS (Inducible T-cell costimulator), LAG-3 (Lymphocyte-activation gene 3), PD-L1 (Programmed death-ligand 1), PD-L2 (Programmed death-ligand 2), PD-1 (Programmed cell death protein 1), TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), TLR-2 (Toll like receptor 2)
Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Features and Benefits
- High-Plex Immune Profiling: Simultaneously quantify 17 key checkpoint proteins (e.g., PD-1, CTLA-4, LAG-3, TIM-3) in a single run, streamlining analysis of co-stimulatory and co-inhibitory pathways.
- Luminex®xMAP® Technology: Leverage bead-based multiplexing for high-throughput, reproducible detection with minimal sample volume (25 μL/well).
- Configurable Panels: Select specific analytes from the 17-plex panel to tailor assays to your research focus, optimizing cost and efficiency.
- Accelerate Translational Research: Unlock insights into immune checkpoint dynamics in cancer, autoimmunity, and immunotherapy efficacy.
- Biomarker Discovery Powerhouse: Identify putative biomarkers (e.g., soluble PD-L1, CTLA-4) for patient stratification or treatment monitoring.
Legal Information
Disclaimer
Label License/Sticker for Assay Product:
By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
signalword
Danger
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2
target_organs
Respiratory Tract
存储类别
10 - Combustible liquids
wgk
WGK 3
法规信息
相关内容
Discover the benefits of MILLIPLEX® multiplex assays, based on Luminex® xMAP® multiplex assay technology, that provide consistent, high-quality results and see how these multiplex biomarker Luminex® assays are being used to advance research.
Research evaluating immune checkpoints may help identify those likely to benefit from PD-1/PD-L1 immunotherapy and reveal new immunotherapy targets for future investigation. See how the MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel 2 was used to multiplex immune checkpoint molecules for NSCLC research.
评估免疫检查点有助于明确在PD-1/PD-L1免疫疗法中获益的患者,并为后续研究揭示新的免疫治疗靶点。了解如何使用MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel 2进行免疫检查点分子的多重检测评估来研究NSCLC疗法。
Discover cancer research resources with modeling and profiling tools for cell culture, genomics, biomarkers, and more to help maximize your cancer research.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持


